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Abstract 
Background: The simultaneous presence of a heterozygous β‑thalassemia with α‑gene triplication may cause any‑
thing from a thalassemia trait to thalassemia intermedia of mild to moderate severity.
Case presentation: An 8‑month‑old ethnic Gypsy male infant with failure to thrive from birth, mild jaundice and 
splenomegaly. Clinical signs were compatible with severe microcytic anemia requiring bi‑monthly blood transfusions. 
The β‑thalassemia gene analysis found homozygous mutation IVS‑I‑110 (G>A) (c.93‑21G>A) in intron 1 of the hemo‑
globin beta globin gene and a non‑pathogenic sequence variant (single nucleotide polimorfism (SNP) Rs1609812). 
In addition, the patient had α gene triplication (αααanti 3.7/αα) caused by double heterozygosity for a 3.7 kb frag‑
ment that contained only the hemoglobin alpha globin gene‑2 gene. This finding led to screening and follow up in 
first‑degree relatives, twin brothers and a sister and parents to provide them with appropriate genetic counseling. 
Nowadays, new horizons could open a new therapeutic management until definitive cure of these diseases through 
gene therapy or mutation‑specific genome editing.
Conclusions: Genetic testing can provide an early diagnosis and facilitates the search for a suitable donor for 
transplantation.
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Background
Thalassemia syndromes are a group of hemoglobi-
nopathies characterized by gene defects that disrupt 
hemoglobin synthesis. β-thalassemia results from insuf-
ficient (β+) or absent (β0) synthesis of normal hemo-
globin chains. The molecular basis involves mutations in 
β-globin genes (mostly point mutations). Most patients 
are from Mediterranean countries, Southeastern Europe, 
Arab and Asian countries [1]. Hematological changes do 
not show up before patients are 3–6 months old [1, 2].
The imbalance between the α- and β-globin chains 
is central to the pathophysiology of β-thalassemia. In 
homozygous β-thalassemia, the excess of α-globin chains 
precipitates on the membranes of the red cell precursors 
of the bone marrow causing hemolysis, ineffective eryth-
ropoiesis and anemia [3, 4].
There are still some unknown aspects in the relation-
ship between genotype and phenotype in thalassemias, 
such as the simultaneous presence of heterozygous 
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β-thalassemia with triple α-gene. This combination may 
cause anything from a thalassemia trait to thalassemia 
intermedia of mild to moderate severity, as in the case 
presented here.
Case presentation
An 8-month-old male infant, Portuguese of gypsy eth-
nic origin, who presented with marked failure to thrive 
from birth, mild jaundice of the skin and splenomegaly 
(greatest longitudinal diameter was 87 mm at 7 months). 
An initial differential diagnosis was made to distinguish 
between hemoglobinopathies and other types of anemia 
(deficiency anemia, hemolytic anemia, erythroblasto-
penia). The clinical signs were compatible with severe 
microcytic anemia, requiring bi-monthly blood trans-
fusions from the time of diagnosis. Admission to hos-
pital was needed on several occasions due to infectious 
episodes (gastroenteritis due to Salmonella, Parvovi-
rus B19 seroconversion) and for the implantation of an 
intravenous (IV) reservoir because of the transfusion 
requirements.
Blood parameters were analyzed with the COULTER 
LH 780 Series (Beckman), a hematology analyzer used to 
count and determine the size of blood cells. Hemoglobin 
analysis and the quantification of hemoglobin (Hb) A2 
and Hb F were performed using Minicap Flex Piercing 
(Sebia) capillary electrophoresis.
The analysis of deoxyribonucleic acid (DNA), taken 
from peripheral blood with ethylenediaminetetraacetic 
acid (EDTA), was performed using proteolytic digestion 
followed by purification and ethanol precipitation. Next, 
spectrophotometry was applied to quantify the obtained 
DNA. All coding exons and adjacent intronic regions of 
the HBB gene (hemoglobin beta globin gene) as well as 
the CACC-box (cytosine-adenine-cytosine-cytosine-box) 
in the proximal promoter region and 5′UTR and 3′UTR 
regions were amplified using PCR (polymerase chain 
reaction).
In the testing for α-thalassemia, hybridization of the 
DNA that was obtained was performed using specific 
probes that are complementary to chromosomal region 
16 p13.3, which contains the HBA (hemoglobin alpha 
globin) gene cluster. Subsequently PCR amplification of 
the genes located in the HBA gene cluster was performed 
using the MLPA (multiplex ligation-dependent probe 
amplification) technique.
Lastly, sequencing of both strands of the amplified frag-
ments was performed and the sequences were visualized 
by capillary electrophoresis using the Applied Biosys-
tems© 3500 Dx Genetic Analyzer.
Labgenetics (Laboratorio de Genética Clínica S.L.) 
performed the genetic testing to diagnose α- and 
β-thalassemia.
The patient’s laboratory findings when he was 8 months 
old were as follows: microcytic anemia without other 
laboratory abnormalities, with Hb 6.2  g/dL, hematocrit 
(Hct) 20  %, mean corpuscular volume (MCV) 74.40 fL, 
mean corpuscular hemoglobin (MCH) 22.90 pg, without 
iron deficiency. HbA2 1.7 %, HbF 90.0 % (see Fig. 1). Bio-
chemical values revealed: lactate dehydrogenase (LDH) 
49 mg/dL, total bilirubin (TBIL) 1.40 mg/dL, direct bili-
rubin (DBIL) 0.31  mg/dL and reticulocytosis (4.14  %) 
(see Table 1).
The β-thalassemia gene analysis found homozygous 
mutation IVS-I-110 (G>A), (c.93-21G>A), in intron 1 of 
the HBB gene and a non-pathogenic sequence variant 
[SNP (Single nucleotide polimorfism) Rs1609812], with 
heterozygous mutation IVS-II-666 (T>C) in intron 2 of 
the HBB gene.
Mutation IVS-I-110 (G>A), (c.93-21G>A), in intron 1 
of the HBB gene can cause protein splicing defects, lead-
ing to aberrant mRNA (ribonucleic acid) and thus result 
in the synthesis of a non-functional protein. The pres-
ence of this homozygous mutation implies a diagnosis of 
β-thalassemia major. The presence of α gene triplication 
in heterozygosis has no effect on the synthesis of α globin 
chains in hemoglobin and subjects are usually clinically 
asymptomatic. However, the combination of a triplicated 
α-globin gene together with heterozygous β-thalassemia 
may produce a thalassemia intermedia phenotype, as 
it increases the imbalance between the α- and β-globin 
chains [4, 5].
At the age of 2 years the child required monthly trans-
fusions and had marked failure to thrive (weight and 
height below P3, head circumference P10), spleno-
megaly and required chelation therapy with Deferasirox 
EXJADE® (deferasirox) (10  mg/kg/day) as maintained 
iron overload was found. The study of the whole family is 
normally done routinely.
The subject had two twin brothers (fraternal twins) 
aged 5  years, who were clinically asymptomatic at the 
time the analysis of the index case was performed (see 
Fig. 2, the family gave its consent to carrying out the fam-
ily tree as part of routine study). Laboratory tests revealed 
they had mild microcytic anemia (Hb 9.3–10.8  g/dL, 
Hct 29.8–34.9 %, MCV 58.80 fL, MCH 18.20–22.90 pg) 
(see Table 1; Fig. 1b). Gene testing in both revealed that 
they had heterozygous mutation IVS-I-110 (G>A), (c.93-
21G>A), in intron 1 of the HBB gene and were homozy-
gous for α-gene triplication (αααanti 3.7/αααanti 3.7).
The heterozygous mutation IVS-I-110 (G>A), (c.93-
21G>A), in intron 1 of the HBB gene can result in the 
synthesis of a non-functional aberrant protein. This 
nucleotide change has been described as a mutation 
associated with the development of β-thalassemia. The 
homozygous α-gene triplication (αααanti 3.7/αααanti 3.7) 
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Fig. 1 HPLC images of (a) index case, mother and father, (b) sister and brothers (twins)
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causes an increase in the synthesis of the α-globin chain 
of hemoglobin, leading to a slight increase in the level 
of hemoglobin in the blood and resulting in an imbal-
ance in α- and β-chain hemoglobin synthesis. The com-
bination of a homozygous or heterozygous triplicated 
α-globin gene together with heterozygous β-thalassemia 
would produce a thalassemia intermedia phenotype, as 
the imbalance between the α- and β-globin chains would 
increase [4, 5].
The subject also had a 9-year-old sister (see Fig. 2) with 
thalassemia minor who was clinically asymptomatic, she 
had a microcytic anemia without other laboratory abnor-
malities (Hb 10.0 g/dL, Hct 31.9 %, MCV 58.0 fL, MCH 
18.30 pg, HbA2 5.5 %, HbF 2.6 %, HbA 91.9) (see Table 1; 
Fig.  1a), and she had at least a triplicated alpha globin 
gene in heterozygosis. The mother was diagnosed with 
thalassemia minor and she also presented with severe 
iron deficiency because of menorrhagia that often needed 
to be treated with intravenous iron (Hb 8.5  g/dL, Hct 
27.5, MCV 68.8 fL, MCH 21.30 pg, HbA2 4.9 % and HbF 
1.4 %) (see Table 1; Fig. 1a, b). The genetic study revealed 
heterozygosity for the IVS-I-110 (G>A) (c.93-21G>A) 
mutation in intron 1 of the HBB gene and heterozygosity 
for alpha-gene triplication (ααα3.7/αα).
The father was clinically asymptomatic and labora-
tory tests showed he had mild microcytic anemia (Hb 
11.2 g/dL, Hct 35.9 %, MCV 60.90 fL, MCH 19 pg) (see 
Table 1; Fig. 1a). He had heterozygosity for the IVS-I-110 
(G>A) (c.93-21G>A) mutation in intron 1 of the HBB 
gene and was homozygous for alpha-gene triplication 
(ααα3.7/ααα3.7). Blood samples were taken from parents 
and sibilings as a part of routine care of patient. Parents 
signed informed consent for molecular genetic studies 
for themselves and their children.
Discussion
The index case presented with failure to thrive (he was 
below the percentile for his sex and age) and was diag-
nosed with severe microcytic anemia. His transfusion 
requirements have increased and at present are required 
on a monthly basis. At the age two he started chela-
tion therapy with deferasirox (10 mg/kg/day) due to the 
progressive increase in serum ferritin levels and other 
parameters indicative of iron overload. Chelation ther-
apy for the treatment of iron overload in patients with 
β-thalassemia is indicated from the age of 2 years, follow-
ing lab tests to rule out changes in renal and liver func-
tion [6]. This treatment is well tolerated by the patient, 
Table 1 Analytical results of the index case and family
Index case 
(8 months old)
Twin 1 Twin 2 Sister Mother Father Rev. values
Gender ♂ ♂ ♂ ♀ ♀ ♂ –
α genotype αααanti 3.7/αα αααanti3.7/αααanti3.7 αααanti3.7/αααanti3.7 Αααanti3.7/‑ αααanti3.7/αα αααanti3.7/αααanti3.7 –
β genotype β+/β+ β+/N (normal) β+/N (normal) – β+/N (normal) β+/N (normal) –
HbA2 1.7 5.6 5.70 5.5 4.7 5.4 –
HbF 90.0 3.10 3.20 2.60 1.1 2.3 –
Hb (gr/dL) 6.2 10.8 9.3 10.0 8.5 11.2 13.2–18.0
Hct (%) 20.0 34.9 29.8 31.9 27.5 35.9 39.0–51.0
Red blood cells 
(×109/L)
2.68 5.92 5.11 5.47 4.00 5.89 4.32–5.66
MCV (fL) 74.40 58.80 58.20 58.40 68.80 60.90 80.0–98.0
MCH (pg) 22.90 18.20 18.20 18.30 21.30 19 27.30–32.60
Reticulocytes (%) 4.14 1.57 2.30 2.70 3.65 – 0.80–2.50
Leukocytes 
(×109/L)
16.0 10.9 12.1 6.40 8.6 8.4 3.7–9.5
Platelets (×109/L) 150 351 398 238 263 230 125–450
Ferritin (ng/mL) 99.9 64.2 95.8 147.7 16.2 743.4 12–300
LDH (mg/dL) 449 350 388 369 233 – 180–430
Total bilirubin (mg/
dL)
1.40 0.37 1.01 1.35 0.60 – 0.30–1.20
Direct bilirubin 
(mg/dL)
0.31 0.09 – 0.26 – – 0.0–0.20
Clinical signs and 
symptoms
Severe anemia, 






Mild anemia Moderate anemia, 
menorrhagia
Mild anemia –
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and can be given orally without need of discontinuation 
of other treatment; in subsequent follow up showed no 
effect on creatinine and transaminase levels. In adition, 
this drug dose has been adjusted to the subject’s weight, 
with good response to ferritin levels, but it has not been 
made liver MRI (magnetic resonance imaging).
Given the patient’s condition and since β-thalassemia 
major was confirmed by genetic testing, we decided to 
perform an HLA study in family members in order to 
undertake allogeneic hematopoietic stem cell transplan-
tation from a related donor. The index case was found 
to be an identical HLA match to his twin brothers, but 
screening for hemoglobinopathies and genetic testing 
found that the brothers had heterozygous β-thalassemia 
together with α-gene triplication (see Fig. 1b; Table 1). For 
this reason it was decided that the brothers would not be 
suitable donors for a hematopoietic stem cell transplan-
tation as this combination of inherited factors involves a 
broad clinical spectrum that is highly unpredictable, so at 
this time we cannot be certain about the clinical implica-
tions of the donors also being affected by the condition, 
despite being asymptomatic at present. The search for an 
unrelated donor was made in the Bone Marrow Donors 
Registry (Registro de donantes de médula ósea, REDMO) 
and a suitable candidate was found.
Although there have been numerous advances in the 
molecular characterization of thalassemia, at present 
certain aspects of the relationship between genotype 
and phenotype remain unknown; one of these is the 
simultaneous presence of a heterozygous β-thalassemia 
with α-gene triplication. This interaction may cause 
anything from a thalassemia trait to thalassemia inter-
media of mild to moderate severity [3, 4, 7]. However, 
the index case has the homozygous mutation IVS-I-110 
(G>A), (c.93-21G>A) and the presence of α gene tripli-
cation in heterozygosis, this genetic association clinically 
manifested as severe anemia. And his brothers presented 
the heterozygous mutation IVS-I-110 (G>A) and α gene 
triplication, and they have an anemia less severe. Per-
haps we should consider the role of the mutation IVS-I-
110 (G>A) and its association with α gene triplication in 
terms of clinical character. The insufficient growth may 
have many causes and a transfusion per month may be 
normal in a major patient [8].
β-thalassemia is a benign congenital blood disorder, 
but patients with β thalassemia major need regular blood 
transfusions throughout their whole lives and this leads 
to iron overload that causes progressive organ dysfunc-
tion. With the currently available treatments, over 80 % 
of subjects have a life expectancy of more than 35 years 
[9, 10]. Still, the only curative treatment for the disease 
is hematopoietic stem cell transplantation. Subjects who 
have an HLA-identical healthy sibling are candidates for 
transplantation, although if this is not the case, at present 
unrelated donor transplant outcomes are very promising, 
expanding the possibilities for these patients [10, 11].
These genetic and clinical findings have impor-
tant implications for prenatal screening and genetic 
Fig. 2 Pedigree with the results for family members
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counseling programs. Families in which heterozygosity 
for α-gene triplication and β-thalassemia coexists in both 
parents may have a child with thalassemia intermedia 
or major. In our case, it is essential to provide adequate 
genetic counseling to the family because of their fam-
ily history for the disease, which in some cases has even 
required bone marrow transplantation (see Fig.  2). It is 
also necessary to provide them with an explanation of the 
clinical implications of the disease and, in case of preg-
nancy, to offer them the possibility of having prenatal 
genetic testing performed on the fetus [4].
Mettananda et  al. reported the reduction of α-globin 
expression would ameliorate the clinical severity of 
patients with β-thalassemia. It seems that therapeu-
tic regulation of α-globin expression is feasible by RNA 
interference, epigenetic drug targeting, or genome edit-
ing. Therefore, exploring new horizons could open a 
new therapeutic management until definitive cure of 
these diseases through gene therapy or mutation-specific 
genome editing [12].
Conclusions
The simultaneous presence of a heterozygous 
β-thalassemia with α-gene triplication may cause differ-
ences in the genotype-phenotype correlation this is why 
genetic testing can provide an early diagnosis and facili-
tates the search for a suitable donor for transplantation 
when needed (for example, of hematopoietic stem cells).
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